Short-Term Results Comparing MTA and Biodentine for Complete Pulpotomy Treatment in Adults Aged 18 to 40 with Symptomatic Irreversible Pulpitis

What this Trial Is About

Researchers are evaluating the short-term outcomes of complete pulpotomy treatments using two different materials, Mineral Trioxide Aggregate MTA and Biodentine, in patients with symptomatic irreversible pulpitis. This trial aims to compare these treatments to understand their effects on pain and healing in affected molar teeth. The study is a randomized controlled trial conducted by Dow University of Health Sciences, focusing on adults aged 18 to 40 years with moderate to severe tooth pain. The treatment involves two visits performed by a single dentist. Initially, patients receive a local anesthetic to prevent discomfort, and a rubber sheet is used to keep the area clean. The dentist removes the decayed part of the tooth and infected tissue, controls bleeding, and places either MTA or Biodentine inside the tooth. A temporary filling is applied, followed by a final filling in the next visit. X-rays are taken to assess the treatment results. Patients may take ibuprofen as needed for pain and attend follow-ups at 1 day, 1 week, 1 month, and 3 months to monitor healing. Participants will undergo initial assessments including medical and dental history, pain rating on a scale of 1 to 10, sensitivity tests like cold and electric pulp tests, and X-rays. After treatment, the healing process is regularly checked through follow-up visits and imaging. The primary outcome is the short-term success of the pulpotomy over three months. Patients are monitored closely to ensure proper healing and pain management throughout the study period.

Short Term Comparative Assessment of MTA and Biodentine in Complete Pulpotomy for Symptomatic Irreversible Pulpitis